LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) posted its earnings results on Thursday. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49, Zacks reports. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular updated its FY 2025 guidance to 2.150-2.320 EPS and its Q1 2025 guidance to 0.480-0.530 EPS.
LeMaitre Vascular Stock Down 3.0 %
LeMaitre Vascular stock traded down $3.14 on Thursday, hitting $99.91. The company’s stock had a trading volume of 197,639 shares, compared to its average volume of 137,081. The firm has a market cap of $2.25 billion, a P/E ratio of 54.60, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96. The company has a fifty day moving average price of $96.75 and a 200-day moving average price of $94.62. LeMaitre Vascular has a one year low of $62.39 and a one year high of $109.58.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on LMAT shares. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Barrington Research boosted their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Oppenheimer reiterated an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $94.63.
About LeMaitre Vascular
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Recommended Stories
- Five stocks we like better than LeMaitre Vascular
- What is a Low P/E Ratio and What Does it Tell Investors?
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Growth Stocks: What They Are, Examples and How to Invest
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Short Selling – The Pros and Cons
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.